Stock Comparison
SMMT vs UNH
Summit Therapeutics Inc vs UnitedHealth Group Inc
Who's the better investment? Let's break it down.
The Verdict
SMMT takes this one.
It's not even close. SMMT outscores UNH by 8.4 points. That's a significant gap in our deep value framework.
Want to compare any two stocks?
Sign up free — get 3 DVR analyses/day, 1800+ stocks, portfolio roast. No credit card.
Valuation
SMMT
Metric
UNH
Market Cap
P/E Ratio
Lower may indicate better value
Forward P/E
Price/Book
EV/EBITDA
Profitability & Growth
SMMT
Metric
UNH
Profit Margin
Gross Margin
Operating Margin
Return on Equity
Return on Assets
Revenue Growth
EPS
Financial Health
SMMT
Metric
UNH
Debt-to-Equity
Lower = less leverage
Current Ratio
Above 1.0 is healthy
Beta
Lower = less volatile
Dividend Yield
Risk Comparison
SMMT
UNH
What Could Go Wrong
The ongoing DOJ criminal and civil investigation, if it leads to significant penalties, forced divestitures, or operational restrictions, could severely impact Optum's growth trajectory and UNH's over...
Red Flags
- 🚩DOJ criminal and civil investigation: Presents an unquantified but potentially significant regulator...
- 🚩Reported membership contracting by 1.3 million in 2026 (from secondary source): If verified in futur...
- 🚩Very low insider ownership (0.28%): While common for mega-caps, it suggests less direct alignment wi...
Competitive Moat
SMMT
Rating
🛡️ Narrow
Trend
📈 Expanding
UNH
Rating
🛡️ Wide
Trend
➡️ Stable to Expanding
Investment Thesis
Summit Therapeutics presents a compelling, high-risk, high-reward investment opportunity driven by ivonescimab's potential to become a blockbuster drug in the massive 2nd-line EGFR mutant NSCLC market. With critical regulatory and clinical catalysts approaching in 2026, strong leadership, and a differentiated mechanism, the company is strategically positioned for significant growth, provided it na...
Full SMMT AnalysisIf Optum continues to expand its health services and technology footprint at high-single-digit to low-double-digit rates, while UnitedHealthcare maintains stable profitability and manages its medical loss ratio, then UNH will deliver consistent EPS growth (high-single digits) and dividend increases. This makes UNH a reliable compounder for long-term capital appreciation and income, not a high-grow...
Full UNH AnalysisPrice Targets & Strategy
Price Targets & Entry/Exit Strategy
Sign up free to unlock the full comparison
Growth Catalysts
Growth Catalysts Comparison
Sign up free to unlock the full comparison
Market Sentiment
Market Sentiment Analysis
Sign up free to unlock the full comparison
The Deep Dive
Summit Therapeutics continues to hold significant 10x growth potential, primarily driven by its lead asset, ivonescimab, targeting the large US/EU non-small cell lung cancer (NSCLC) market. The bispecific mechanism provides a strong competitive advantage, and key regulatory milestones like the PDUFA date in November 2026 and HARMONi-3 interim data in Q2 2026 serve as major catalysts. The company maintains a robust cash position and positive free cash flow, supporting its clinical development. Ho...
Full SMMT AnalysisUnitedHealth Group (UNH) remains a robust, high-quality mega-cap in the mature and highly regulated healthcare sector. Q1 2026 adjusted EPS of $7.23, a recent dividend increase to $2.32, and some analyst upgrades (e.g., Truist to $440, Goldman Sachs Conviction Buy) reflect solid operational performance and financial strength. However, these are characteristics of a stable compounder, not a company capable of 10x growth within 3-5 years. Its immense scale, market maturity, and regulatory landscap...
Full UNH AnalysisWant More Comparisons?
Run any stock through our deep value analyzer.
Not Financial Advice
This comparison is for educational purposes only. We are not financial advisors. Always do your own research and consult a qualified financial advisor before making investment decisions.